Manuel Delgado-Alvarado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manuel Delgado-Alvarado has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Benedicto Crespo-Facorro
Biomedical Research Networking Center for Mental Health (CIBERSAM), Madrid, Spain; Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBiS, Sevilla, Spain
3 shared publicationsJavier Riancho
Neurology Department Sierrallana Hospital Torrelavega Spain
3 shared publications- Javier Riancho
Hospital General Sierrallana-IDIVAL, Torrelavega, Spain
3 shared publications Jacqueline Mayoral-Van Son
Service of Neurology, Hospital Sierrallana, Torrelavega, Spain; Instituto de Investigación Sanitaria Valdecilla-IDIVAL, Santander, Spain; Biomedical Research Networking Center for Mental Health (CIBERSAM), Madrid, Spain; Psychiatry Department, University Hospital Marqués de Valdecilla, Spain
2 shared publications- Javier Labad
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, UAB, Mataró, Spain
2 shared publications Javier Vázquez-Bourgon
Instituto de Investigación Sanitaria Valdecilla-IDIVAL, Santander, Spain; Biomedical Research Networking Center for Mental Health (CIBERSAM), Madrid, Spain; Psychiatry Department, University Hospital Marqués de Valdecilla, Spain
2 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (3) , 360-362
A Novel GNAO1 Variant Associated With Variable and Mild Phenotypes in a Spanish Family
A Novel GNAO1 Variant Associated With Variable and Mild Phenotypes in a Spanish Family
- 31 July 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (3) , 360-362
Open AccessA Novel GNAO1 Variant Associated With Variable and Mild Phenotypes in a Spanish Family
A Novel GNAO1 Variant Associated With Variable and Mild Phenotypes in a Spanish Family
- 14 April 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study
Background: Resistant chronic migraine remains a major therapeutic challenge, particularly in patients who continue to be symptomatic despite OnabotulinumtoxinA. Anti–calcitonin gene–related peptide (CGRP) monoclonal antibodies may provide effective preventive options, but comparative real-world data and quantification of acute medication reduction remain limited. Objective: To compare the real-world effectiveness of erenumab versus galcanezumab in patients with chronic migraine refractory to OnabotulinumtoxinA and to evaluate changes in acute medication use. Methods: We conducted a retrospective observational study of consecutive patients treated at a neurology outpatient clinic in Cantabria, Spain (ethics approval code 2022.204). Monthly migraine days (MMD) were recorded at baseline and during 3 follow-up visits. Acute medication use (monthly units of triptans and NSAIDs) was obtained from the electronic prescription dispensing system for the 6 months before and after treatment initiation. Changes in MMD were analyzed using a linear mixed-effects model. Acute medication changes were analyzed using a 2-way repeated-measures ANOVA (time pre/post × treatment group). Results: Forty-five patients were included (erenumab n = 24; galcanezumab n = 21). Mean MMD decreased from 20.1 ± 7.9 at baseline to 8.0 ± 6.6, 8.1 ± 7.3, and 6.4 ± 7.7 at visits 1–3 ( P < 0.001), with no between-group differences (group P = 0.576; interaction P = 0.524). Across visits, ≥50% responder rates ranged from 57.1% to 85.0% and ≥75% responder rates from 35.0% to 57.1%, with no differences between treatments (all P > 0.05). Triptan use decreased significantly over time ( P = 0.033), whereas NSAID use did not ( P = 0.344). Conclusion and relevance: In patients with chronic migraine refractory to OnabotulinumtoxinA, erenumab and galcanezumab produced comparable and sustained reductions in migraine frequency, with high responder rates. Treatment was associated with reduced triptan use, supporting the clinical relevance of anti-CGRP monoclonal antibodies in this population.
- 14 April 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study
Background: Resistant chronic migraine remains a major therapeutic challenge, particularly in patients who continue to be symptomatic despite OnabotulinumtoxinA. Anti–calcitonin gene–related peptide (CGRP) monoclonal antibodies may provide effective preventive options, but comparative real-world data and quantification of acute medication reduction remain limited. Objective: To compare the real-world effectiveness of erenumab versus galcanezumab in patients with chronic migraine refractory to OnabotulinumtoxinA and to evaluate changes in acute medication use. Methods: We conducted a retrospective observational study of consecutive patients treated at a neurology outpatient clinic in Cantabria, Spain (ethics approval code 2022.204). Monthly migraine days (MMD) were recorded at baseline and during 3 follow-up visits. Acute medication use (monthly units of triptans and NSAIDs) was obtained from the electronic prescription dispensing system for the 6 months before and after treatment initiation. Changes in MMD were analyzed using a linear mixed-effects model. Acute medication changes were analyzed using a 2-way repeated-measures ANOVA (time pre/post × treatment group). Results: Forty-five patients were included (erenumab n = 24; galcanezumab n = 21). Mean MMD decreased from 20.1 ± 7.9 at baseline to 8.0 ± 6.6, 8.1 ± 7.3, and 6.4 ± 7.7 at visits 1–3 ( P < 0.001), with no between-group differences (group P = 0.576; interaction P = 0.524). Across visits, ≥50% responder rates ranged from 57.1% to 85.0% and ≥75% responder rates from 35.0% to 57.1%, with no differences between treatments (all P > 0.05). Triptan use decreased significantly over time ( P = 0.033), whereas NSAID use did not ( P = 0.344). Conclusion and relevance: In patients with chronic migraine refractory to OnabotulinumtoxinA, erenumab and galcanezumab produced comparable and sustained reductions in migraine frequency, with high responder rates. Treatment was associated with reduced triptan use, supporting the clinical relevance of anti-CGRP monoclonal antibodies in this population.
- Open Access
- 30 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6150
Novel Association of the Presenilin-1 (Leu282Arg) Mutation with Isolated Spastic Paraparesis: Case Presentation and Review of Current Evidence
Background: Although Presenilin-1 (PSEN1) mutations are classically associated with early-onset Alzheimer’s disease (AD), spastic paraparesis (SP) may occasionally represent as an initial or even isolated clinical manifestation. Methods: We report the novel association of a PSEN1 mutation (Leu282Arg) with isolated SP at onset in a patient with a family history of early-onset AD. Additionally, we reviewed previously published cases describing similar presentations related to PSEN1 mutations. Results: The age of reported patients ranged from 24 to 60 years. The most common clinical course included the presence of cotton wool plaques and a progressive development of cognitive decline following the onset of SP. A positive family history of either motor or cognitive symptoms was consistently observed. Conclusions: Our findings emphasize the clinical importance of considering PSEN1 mutations in the differential diagnosis of patients presenting with spastic paraparesis, particularly in the presence of cognitive symptoms, cerebral amyloid angiopathy, or a family history of AD.
- 30 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6150
Open AccessNovel Association of the Presenilin-1 (Leu282Arg) Mutation with Isolated Spastic Paraparesis: Case Presentation and Review of Current Evidence
Background: Although Presenilin-1 (PSEN1) mutations are classically associated with early-onset Alzheimer’s disease (AD), spastic paraparesis (SP) may occasionally represent as an initial or even isolated clinical manifestation. Methods: We report the novel association of a PSEN1 mutation (Leu282Arg) with isolated SP at onset in a patient with a family history of early-onset AD. Additionally, we reviewed previously published cases describing similar presentations related to PSEN1 mutations. Results: The age of reported patients ranged from 24 to 60 years. The most common clinical course included the presence of cotton wool plaques and a progressive development of cognitive decline following the onset of SP. A positive family history of either motor or cognitive symptoms was consistently observed. Conclusions: Our findings emphasize the clinical importance of considering PSEN1 mutations in the differential diagnosis of patients presenting with spastic paraparesis, particularly in the presence of cognitive symptoms, cerebral amyloid angiopathy, or a family history of AD.
- 5 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1190-1192
Overcoming Absorption Issues: Success with Inhaled Levodopa in a Gastrectomized PD Patient
- 5 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1190-1192
Overcoming Absorption Issues: Success with Inhaled Levodopa in a Gastrectomized PD Patient
- 24 May 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (21) , 892-893
Parkinsonism Associated With Striatal Enlarged Perivascular Spaces
- 24 May 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (21) , 892-893
Parkinsonism Associated With Striatal Enlarged Perivascular Spaces
- 1 July 2021
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
- Vol. 14 (3) , 179-180
Predictive value of prolactin in first episode psychosis at ten years follow-up
- 1 July 2021
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
- Vol. 14 (3) , 179-180
Predictive value of prolactin in first episode psychosis at ten years follow-up
- 1 July 2021
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 14 (3) , 179-180
Predictive value of prolactin in first episode psychosis at ten years follow-up
- 1 July 2021
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 14 (3) , 179-180
Predictive value of prolactin in first episode psychosis at ten years follow-up
- 21 September 2020
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (12) , 3779-3781
A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability
Myoclonus-dystonia associated with epsilon-sarcoglycan gene (SGCE) is a rare disorder characterized by myoclonus involving the upper body (neck, trunk, upper limbs) and proximal muscles associated with dystonia in more than half of the patients. When the clinical picture is clearly identified, more than half of the cases are associated with mutations in the SGCE gene. We herein describe a family with myoclonus-dystonia associated with a novel mutation in exon 7 of SGCE, c.904A>T (p.Lys302Ter) [Chr7:(GRCh38):g.94600779 T>A], which was absent in a non-affected member. A video recording of two of the affected members is provided. While the index case presents a severe cervical dystonia even affecting back posture, his sibling shows a much milder phenotype with mild myoclonic jerks. None of them had alcohol responsiveness or psychiatric comorbidity.
- 21 September 2020
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (12) , 3779-3781
A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability
Myoclonus-dystonia associated with epsilon-sarcoglycan gene (SGCE) is a rare disorder characterized by myoclonus involving the upper body (neck, trunk, upper limbs) and proximal muscles associated with dystonia in more than half of the patients. When the clinical picture is clearly identified, more than half of the cases are associated with mutations in the SGCE gene. We herein describe a family with myoclonus-dystonia associated with a novel mutation in exon 7 of SGCE, c.904A>T (p.Lys302Ter) [Chr7:(GRCh38):g.94600779 T>A], which was absent in a non-affected member. A video recording of two of the affected members is provided. While the index case presents a severe cervical dystonia even affecting back posture, his sibling shows a much milder phenotype with mild myoclonic jerks. None of them had alcohol responsiveness or psychiatric comorbidity.
- 1 January 2020
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 70, 74-81
Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders
- 1 January 2020
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 70, 74-81
Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders
- 26 November 2019
- Published by Wiley in Movement Disorders
- Vol. 35 (2) , 204-214
Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review
Freezing of gait is a disabling phenomenon that appears in a substantial number of Parkinson's disease (PD) patients as the disease evolves. It is considered to be one of the most relevant contributing factors to worsening of quality of life. Current pharmacological or surgical treatment options have limited efficacy. Thus, alternative nonpharmacological/nonsurgical approaches have emerged in recent years in an attempt to improve quality of life in PD. This systematic review summarizes studies of such therapies over the past 5 years. Thirty‐five studies were evaluated by use of a qualitative evaluation, while the methodological quality was assessed using validated tools. According to our results, there appear to be two broad categories of nonpharmacological therapies: those that seek a long‐lasting benefit and those that aim to achieve a transient effect to overcome the freezing of gait episode. Among the former, it is possible to differentiate between “passive” therapies, which include transcranial magnetic stimulation or transcranial direct current stimulation, and “active” therapies, which are based on different cognitive or physical training programs. Finally, “transient effect” therapies use different types of cues, such as visual, auditory, or proprioceptive stimuli, to attempt to shift the patient's habitual motor control to a goal‐directed one. In conclusion, a broad spectrum of nonpharmacological/nonsurgical approaches for freezing of gait has emerged in recent years with promising results. © 2019 International Parkinson and Movement Disorder Society
- 26 November 2019
- Published by Wiley in Movement Disorders
- Vol. 35 (2) , 204-214
Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review
Freezing of gait is a disabling phenomenon that appears in a substantial number of Parkinson's disease (PD) patients as the disease evolves. It is considered to be one of the most relevant contributing factors to worsening of quality of life. Current pharmacological or surgical treatment options have limited efficacy. Thus, alternative nonpharmacological/nonsurgical approaches have emerged in recent years in an attempt to improve quality of life in PD. This systematic review summarizes studies of such therapies over the past 5 years. Thirty‐five studies were evaluated by use of a qualitative evaluation, while the methodological quality was assessed using validated tools. According to our results, there appear to be two broad categories of nonpharmacological therapies: those that seek a long‐lasting benefit and those that aim to achieve a transient effect to overcome the freezing of gait episode. Among the former, it is possible to differentiate between “passive” therapies, which include transcranial magnetic stimulation or transcranial direct current stimulation, and “active” therapies, which are based on different cognitive or physical training programs. Finally, “transient effect” therapies use different types of cues, such as visual, auditory, or proprioceptive stimuli, to attempt to shift the patient's habitual motor control to a goal‐directed one. In conclusion, a broad spectrum of nonpharmacological/nonsurgical approaches for freezing of gait has emerged in recent years with promising results. © 2019 International Parkinson and Movement Disorder Society